Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency by Veiga-da-Cunha, Maria et al.
Failure to eliminate a phosphorylated glucose analog
leads to neutropenia in patients with G6PT
and G6PC3 deficiency
Maria Veiga-da-Cunhaa,b,1, Nathalie Chevaliera,b, Xavier Stephennec, Jean-Philippe Defourb,d, Nicole Pacziae,
Alina Fersterf, Younes Achourib, Joseph P. Dewulfa,b, Carole L. Linstere, Guido T. Bommera,b, and Emile Van
Schaftingena,b,1
aWalloon Excellence in Lifesciences and Biotechnology, B-1200 Brussels, Belgium; bGroupe de Recherches Metaboliques, de Duve Institute, UCLouvain
(Université Catholique de Louvain), B-1200 Brussels, Belgium; cService de Gastro-Entérologie et Hépatologie Pédiatrique, Cliniques Universitaires Saint-Luc,
UCLouvain, B-1200 Brussels, Belgium; dBiologie Hématologique, Cliniques Universitaires Saint-Luc, UCLouvain, B-1200 Brussels, Belgium; eLuxembourg
Centre for Systems Biomedicine, Université du Luxembourg, L-4367 Belvaux, Luxembourg; and fDepartment of Hematology/Oncology, Hôpital Universitaire
des Enfants Reine Fabiola, Université Libre de Bruxelles, B-1020 Brussels, Belgium
Edited by Richard G. Kibbey, Yale School of Medicine, New Haven, CT, and accepted by Editorial Board Member Barbara B. Kahn December 5, 2018 (received
for review September 18, 2018)
Neutropenia represents an important problem in patients with
genetic deficiency in either the glucose-6-phosphate transporter of
the endoplasmic reticulum (G6PT/SLC37A4) or G6PC3, an endoplas-
mic reticulum phosphatase homologous to glucose-6-phosphatase.
While affected granulocytes show reduced glucose utilization, the
underlying mechanism is unknown and causal therapies are lacking.
Using a combination of enzymological, cell-culture, and in vivo
approaches, we demonstrate that G6PT and G6PC3 collaborate to
destroy 1,5-anhydroglucitol-6-phosphate (1,5AG6P), a close struc-
tural analog of glucose-6-phosphate and an inhibitor of low-KM
hexokinases, which catalyze the first step in glycolysis in most tis-
sues. We show that 1,5AG6P is made by phosphorylation of 1,5-
anhydroglucitol, a compound normally present in human plasma,
by side activities of ADP-glucokinase and low-KM hexokinases.
Granulocytes from patients deficient in G6PC3 or G6PT accumulate
1,5AG6P to concentrations (∼3 mM) that strongly inhibit hexoki-
nase activity. In a model of G6PC3-deficient mouse neutrophils,
physiological concentrations of 1,5-anhydroglucitol caused massive
accumulation of 1,5AG6P, a decrease in glucose utilization, and cell
death. Treating G6PC3-deficient mice with an inhibitor of the kid-
ney glucose transporter SGLT2 to lower their blood level of 1,5-
anhydroglucitol restored a normal neutrophil count, while adminis-
tration of 1,5-anhydroglucitol had the opposite effect. In conclusion,
we show that the neutropenia in patients with G6PC3 or G6PT mu-
tations is a metabolite-repair deficiency, caused by a failure to elim-
inate the nonclassical metabolite 1,5AG6P.
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Neutrophils play an important role in our defense againstinfections, and neutropenias represent major health threats.
Among the genetic causes of neutropenia, two are due to mu-
tations inactivating G6PC3 (1, 2) and G6PT/SLC37A4 (3), pro-
teins thought to be involved in glucose-6-P metabolism.
G6PC3 is homologous to G6PC1, the well-known glucose-6-
phosphatase that produces glucose from glucose-6-P in the
liver and the kidneys and plays an essential role in glucose
homeostasis. Like G6PC1, G6PC3 is an integral membrane
protein of the endoplasmic reticulum whose catalytic site faces
the lumen of this organelle. Unlike G6PC1, which has a nar-
row tissue distribution limited to the glucose-producing or-
gans, G6PC3 is expressed in virtually all tissues. It is therefore
sometimes referred to as “ubiquitous glucose-6-phosphatase,”
although its glucose-6-phosphatase activity, if detectable, is
low (4–7). G6PC3 deficiency causes a syndrome (severe con-
genital neutropenia type 4) associating neutropenia and neu-
trophil dysfunction with malformations, but has no impact on
glucose homeostasis. In contrast, G6PC1 deficiency leads to
a dramatic impairment of glucose metabolism known as gly-
cogen storage disease type Ia, but not to problems with neu-
trophils (8).
Neutropenia may also be caused by a deficiency in G6PT. This
ubiquitously expressed protein is encoded by the SLC37A4 gene
and transports glucose-6-P from the cytosol to the lumen of the
endoplasmic reticulum, where it can be hydrolyzed by G6PC1 (9)
and possibly G6PC3. Deficiency in G6PT leads to glycogen stor-
age disease type Ib (GSDIb), which associates all of the metabolic
symptoms of G6PC1 deficiency with neutropenia and neutrophil
dysfunction. While the origin of the metabolic symptoms is easily
understandable, the cause of the decrease in neutrophil numbers
and of their impaired function remains a puzzle.
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Neutrophils derived from patients with G6PC3 or G6PT de-
ficiency are characterized by reduced glucose utilization, which is
likely responsible for their decreased capacity to produce su-
peroxide anions, decreased protein glycosylation, and increased
endoplasmic reticulum stress (10, 11). It has been proposed that
lack of functional G6PC3 or G6PT prevents endogenous glucose
formation from glucose-6-P in neutrophils and thereby decreases
the amount of glucose available for glycolysis and the pentose-P
pathway in a way that is vital for neutrophil function (11). What
is unsatisfying with this explanation is that blocking the conver-
sion of glucose-6-P to glucose is expected on the contrary to
increase glucose-6-P availability for glycolysis and the pentose-P
pathway (see also ref. 12).
These considerations led us to hypothesize that the critical
role of G6PC3 and G6PT in neutrophils is to dephosphorylate a
noncanonical phosphate ester that inhibits glucose utilization in
these cells. Many enzymes of intermediary metabolism catalyze
side reactions and produce noncanonical metabolites that are
then destroyed by metabolite-repair enzymes (13, 14). Mutations
in metabolite-repair enzymes lead to the accumulation of side
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Fig. 1. Substrate specificity of G6PC1, G6PC3, and the glucose-6-phosphate transporter. (A) Wild-type (WT) and catalytically inactive (H176A or H167A)
human G6PC1 and G6PC3 were produced as recombinant proteins with a C-terminal 6×His tag in HEK293T cells. Equal amounts of the membrane fraction
were analyzed by Western blotting with anti-6×His antibody. (B) The membrane preparations were used at appropriate concentrations to assay the phos-
phatase activity on the indicated substrates (all tested at 100 μM) through the release of inorganic phosphate. Phosphatase activity observed in preparations
from cells expressing the catalytically dead mutants was assessed under identical conditions and subtracted to account for baseline phosphatase activity. (C)
Ribose-5-P and glucose-6-P phosphatase activities were assayed with a radiochemical assay (10 μM) in rat microsomes from the indicated tissues. (D) Ratios of
the ribose-5-P and glucose-6-P phosphatase activities measured in C are compared with those measured with membrane preparations from HEK293T cells
overexpressing recombinant G6PC3 or G6PC1. (E) Hydrolysis of the best substrates (100 μM) for G6PC3 was assayed in rat skeletal muscle microsomes in the
presence or absence of the G6PT inhibitor S3483 (100 μM) and of 7.5 mM octyl glucoside (OG). For B and C, data are means and error bars are ±SEM (n = 3). For
E, data are means and error bars are ±SD (n ≥ 4). P values (ns, not significant, P > 0.05; *P ≤ 0.05; $P ≤ 0.0001) were determined with unpaired t tests using the
two-stage linear step-up procedure of Benjamini et al. (51), with Q = 1%.
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products (15–19) and in some cases cause metabolic diseases,
like L-2-hydroxyglutaric aciduria (20, 21) and NAD(P)HX
epimerase deficiency (22).
In the current work, we present compelling evidence that the
neutropenia in patients with G6PC3 or G6PT mutations is
caused by a failure to eliminate the noncanonical metabolite 1,5-
anhydroglucitol-6-phosphate (1,5AG6P), which results from the
phosphorylation of 1,5-anhydroglucitol (1,5AG), a glucose ana-
log normally present in blood. Our data indicate that these dis-
eases should be considered as metabolite-repair deficiencies, an
emerging new class of inborn errors of metabolism. Further-
more, understanding the underlying pathogenesis allowed us to
devise a successful treatment strategy in G6PC3-deficient mice.
Results
G6PC3 Has a Wide Substrate Spectrum, but Only a Few Compounds
Are Also Transported by G6PT. The role of G6PC1 as a glucose-6-
phosphatase is well-established (23). In contrast, little is known
about the substrate spectrum of G6PC3. Thus, we started by
comparing the substrate preferences for G6PC3 and G6PC1. As
G6PC3 and G6PC1 are integral membrane proteins, we studied
their kinetic properties in membrane preparations from HEK293T
cells that overexpressed the human recombinant proteins with a
C-terminal 6×His tag. To ensure that the observed phosphatase
activities were genuinely contributed by G6PC1 or G6PC3, we
subtracted baseline phosphatase activities observed in control
cells expressing the respective catalytically dead mutants (H176A
for G6PC1; H167A for G6PC3) where the histidine that tran-
siently accepts a phosphoryl group during the catalytic cycle (24)
is mutated. The abundance of the recombinant proteins was
similar in the membrane preparations used (Fig. 1A), indicating
that their activities could be readily compared without bias.
Phosphatase activity of the recombinant proteins with various
phosphate esters (0.1 mM) was assayed by measuring the release
of inorganic phosphate (Fig. 1B). This confirmed that G6PC1
acts best on glucose-6-P, mannose-6-P, and inorganic pyro-
phosphate and not, or almost not, on the other phosphate esters
that we tested. By contrast, G6PC3 hydrolyzes a wider spectrum
of substrates, and glucose-6-P was clearly not among its best
substrates. Inorganic pyrophosphate, ribose-5-P, ribitol-5-P, and
1,5AG6P were indeed hydrolyzed four to eight times faster than
glucose-6-P, while other phosphate esters were less well but still
significantly hydrolyzed.
Detailed kinetic properties of the two enzymes were de-
termined for the best substrates (SI Appendix, Table S1). Using
apparent Vmax/KM ratio as a criterion (a proxy for catalytic effi-
ciency, which could not be determined because the proteins were
impure), glucose-6-P and inorganic pyrophosphate were at least
10-fold better substrates for G6PC1 than were ribose-5-P and
1,5AG6P. In the case of G6PC3, glucose-6-P was a 4.6-, 8.5-, and
24-fold lesser substrate than 1,5AG6P, ribose-5-P, and inorganic
pyrophosphate, respectively. Since the two proteins were com-
parably expressed in the enzymatic preparations that we used
(Fig. 1A), we could directly compare their activities. For glucose-
6-P, the Vmax/KM ratio was 13-fold higher for G6PC1 than for
G6PC3, while on the contrary it was 13- and 4.6-fold higher for
G6PC3 than for G6PC1 in the case of ribose-5-P and 1,5AG6P,
respectively. Comparable results were obtained with proteins
lacking or carrying an N-terminal 6×His tag (SI Appendix, Fig.
S1), ensuring that the presence of a tag and its location do not
affect the kinetic properties of G6PC3 and G6PC1. Taken to-
gether, our data confirmed the preference of G6PC1 for glucose
6-P, and revealed that G6PC3 is much more efficient on other
substrates such as ribose 5-P and 1,5AG6P.
To confirm that the specificity observed for the human
recombinant proteins corresponded to that of the endogenous
G6PC1 and G6PC3 found in tissues, we prepared microsomes
from rat tissues that express G6PC3 but not G6PC1 (skeletal
muscle, heart, and spleen) or mainly G6PC1 (liver). In these
preparations, we then assessed the capacity to hydrolyze radio-
labeled glucose-6-P and ribose-5-P (Fig. 1C) as surrogate mea-
sures for G6PC1 and G6PC3 activity, respectively. These assays
were performed in the presence of a mild detergent to prevent
any limitation in the entry of substrate into the microsomes. The
ratio of the phosphatase activity on ribose-5-P and glucose-6-P
was between 2.5 and 4 in the case of the microsomes prepared
from skeletal muscle, heart, and spleen but only 0.05 in the case
of the liver microsomes (Fig. 1D). These values were in excellent
agreement with those observed for human recombinant G6PC3
(4.6) and G6PC1 (0.02) tested under the same conditions. These
results indicated that the physiological substrate of G6PC3, un-
like G6PC1, is not glucose-6-phosphate but rather one of the
good substrates that we found.
Neutropenia is found in patients with G6PC3 or G6PT de-
ficiency. In liver and kidney, G6PT transports glucose-6-P into
the endoplasmic reticulum (ER), where it is dephosphorylated
by G6PC1 (23). We therefore reasoned that in other tissues, the
role of G6PT could be to transport a phosphoric ester, a sub-
strate of G6PC3, into the ER. Thus, deficiency of either of these
proteins would lead to the accumulation of this substrate, which
might be toxic to neutrophils and explain neutropenia.
To test this hypothesis, we used a reversible and specific in-
hibitor of G6PT, S3483 (25), and assessed whether G6PT is re-
quired for the hydrolysis of the best substrates for G6PC3 by rat
skeletal muscle microsomes, where G6PC3 is plentiful and
G6PC1 is absent. The activity of skeletal muscle microsomes on
glucose-6-P and 1,5AG6P was significantly inhibited by S3483,
but this was not the case for the phosphatase activity on ribose-5-
P, ribitol-5-P, and inorganic pyrophosphate (Fig. 1E). This in-
dicated that G6PT transports glucose-6-P and its close structural
analog 1,5AG6P but not ribose-5-P, ribitol-5-P, and inorganic
pyrophosphate. Of note, treatment of microsomes with the de-
tergent octyl glucoside (7.5 mM) led to a significant increase in
the phosphatase activity toward ribose-5-P, ribitol-5-P, inorganic
pyrophosphate, and, to a lesser degree, glucose-6-P, suggesting
that, in skeletal muscle microsomes, entry of these metabolites
into the ER is rate-limiting. In contrast, 1,5AG6P dephosphor-
ylation was largely unaffected, likely because G6PT activity
allowed free entry into the ER. Together, this suggested that
1,5AG6P could be the common metabolite that accumulates in
G6PC3 and G6PT deficiency and accounts for the neutropenia
that is found in these conditions.
1,5-Anhydroglucitol-6-Phosphate Accumulates in Human HAP1 Cell
Lines Deficient in G6PC3 or G6PT. To investigate whether G6PC3
or G6PT deficiency leads to the accumulation of 1,5AG6P in
cells, we used CRISPR-Cas9 to generate HAP1 cell lines de-
ficient in either of these two proteins. Sequencing of the DNA
indicated the presence of mutations incompatible with functional
proteins (see SI Appendix, Materials, Methods, and Patient In-
formation for details on the mutations in these cell lines). These
cells were grown with different concentrations of 1,5-anhy-
droglucitol added to the medium. In parallel, we also treated cells
with 1,5-anhydrofructose, which is readily converted to 1,5AG by
1,5-anhydrofructose reductase (26) (see also SI Appendix, Fig. S2).
Metabolites, including 1,5AG6P, were determined by LC-MS (Fig.
2 and SI Appendix, Fig. S2) or by GC-MS (SI Appendix, Fig. S3),
which provided complementary information.
Addition of 1,5AG to the culture media of these cell lines led
to a dose-dependent accumulation of 1,5AG6P in G6PT- or
G6PC3-deficient cell lines, while this phosphate ester remained
at an ∼100-fold lower level in wild-type cells (Fig. 2A). This
demonstrated that 1,5AG is phosphorylated to 1,5AG6P in in-
tact cells, and confirmed our hypothesis that both G6PC3 and
G6PT are required for the hydrolysis of 1,5AG6P.
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In this particular experimental system, even at the highest
concentration of 1,5AG (1 mM), the accumulation of 1,5AG6P
only led to a modest decrease in glucose consumption of the
three mutant cell lines (Fig. 2B). Interestingly, when we added
1,5-anhydrofructose, the precursor of 1,5AG, we observed a
several-fold higher accumulation of 1,5AG6P in G6PC3- or
G6PT-deficient cells (Fig. 2C), reaching ∼2 to 4 mM in the
presence of 0.5 mM 1,5-anhydrofructose (SI Appendix, Fig. S3C)
compared with only ∼0.1 to 0.3 mM when the same cell lines
were cultured with 1 mM 1,5AG (SI Appendix, Fig. S3A), pre-
sumably due to faster entry of 1,5-anhydrofructose into these
cells and its rapid conversion to 1,5AG (SI Appendix, Fig. S2).
Of note, these high concentrations of 1,5AG6P in cells treated
with 0.5 mM 1,5-anhydrofructose led to a 40 to 50% decrease in
glucose consumption in G6PC3- and G6PT-deficient cells and no
change in wild-type cells (Fig. 2D and SI Appendix, Fig. S3D).
Consistent with the idea that 1,5AG6P might inhibit the first step
in glycolysis [i.e., it was previously shown that in vitro 1,5AG6P
inhibited HK1 (27)], we observed a significant reduction of gly-
colytic intermediates (glucose-6-P, fructose-6-P, fructose-1,6-
bisphosphate, 6-phosphogluconate, and ribose-5-P; Fig. 2 E–H
and SI Appendix, Fig. S3 H–J and N) while the concentration of
the Krebs cycle intermediates malate (Fig. 2H), α-ketoglutarate,
and succinate (SI Appendix, Fig. S3 O and P) were largely un-
affected. We also observed that cell viability was decreased when
G6PC3- or G6PT-deficient cells were cultured with 0.5 mM 1,5-
anhydrofructose (Fig. 2I), while little or no toxicity was observed
in wild-type cells or when 1,5AG was used, presumably because
the latter caused a much lower accumulation of 1,5AG6P (Fig. 2
A and C and SI Appendix, Fig. S3 A and C) and smaller effects on
glucose consumption (Fig. 2 B and D and SI Appendix, Fig. S3 B
and D).
Thus, our data demonstrate that G6PC3 and G6PT collabo-
rate to dephosphorylate 1,5AG6P, and that accumulation of high
concentrations of this metabolite (∼3 mM) lead to inhibition of
glycolysis and reduced cell viability.
Toxicity of Physiological Concentrations of 1,5-Anhydroglucitol in an
Immortalized Mouse Neutrophil Precursor Cell Line Deficient in
G6PC3. Even though 1,5AG6P accumulated in G6PC3- or G6PT-
deficient HAP1 cells when 1,5AG was added to the culture media,
1,5AG barely affected glucose metabolism and cell viability, re-
gardless of the use of concentrations that far exceeded the phys-
iological concentration of this polyol in plasma. We hypothesized
that neutrophils might be more sensitive to 1,5AG and more
prone to accumulate 1,5AG6P because of differences in their
hexose transporters and hexose-phosphorylating enzymes. To in-
vestigate this question, we studied Hox8b-immortalized neutrophil
progenitor cell lines from wild-type or G6PC3-deficient mice (28).
Remarkably, in G6PC3-deficient neutrophils, 1,5AG promp-
ted cell death and was about as effective as 1,5-anhydrofructose
in this respect (Fig. 3A). Addition of a physiological concentra-
tion of 1,5AG (0.2 mM) to the culture media resulted in a sig-
nificant decrease in the rate of glucose consumption in G6PC3-
deficient cells but not in wild-type cells (Fig. 3B). Targeted
A
E G
I
HF
B C D
Fig. 2. 1,5-Anhydroglucitol-6-phosphate accumulates in human HAP1 cell lines deficient in G6PC3 or G6PT grown in the presence of 1,5-anhydroglucitol and
leads to inhibition of glycolysis and of the pentose phosphate pathway, and cell death. Wild-type, G6PT-deficient (clone A4), and G6PC3-deficient (clones
D7 and A6) HAP1 cells were cultured for 24 h in DMEM (1 g/L glucose) with or without addition of the indicated concentrations of 1,5AG (A and B) or 1,5-
anhydrofructose (C–H). Growth medium was replaced after 20 h and ∼4 h before the preparation of cell extracts. The indicated intracellular metabolites were
analyzed by LC-MS (A, C, and E–H). Glucose consumption was calculated from the remaining glucose in the medium after 20 h (B and D). LC-MS measurements
were normalized to the untreated conditions (=100%) within the experiment (E–H). Values represent means ± SD of three independent experiments. (I) Cell
survival was measured after 72-h growth in the same media (means ± SD; n = 3). Statistical analysis: (B and D) P values were determined using multiple
unpaired t tests (for each cell line the treated condition was compared with the untreated), and statistical significance was determined using the Holm–Sidak
method, with alpha = 0.05. (A, C, and E–I) P values were determined with two-way ANOVA, and statistical significance was determined using the post hoc
Dunnett’s test for multiple comparisons [comparison of KO with wild type with the same treatment (A, C, and E–H); comparison of the treated with the
untreated condition (I)], with alpha = 0.05. *P ≤ 0.05; ∋P ≤ 0.01; ∞P ≤ 0.001; $P ≤ 0.0001. 1,5-AF, 1,5-anhydrofructose; TIC, total ion current.
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metabolomic analysis by LC-MS showed that the presence of
1,5AG resulted in a time-dependent increase in 1,5AG6P, which
reached ∼3 mM after 22 h (Fig. 3C). In parallel, we observed a
progressive decrease in the concentration of glycolytic metabolites
such as glucose-6-P, fructose-1,6-bisphosphate, and triose-phosphates
in G6PC3-deficient cells (Fig. 3 D–G) but no significant change in
the concentration of Krebs cycle intermediates, as illustrated for
fumarate (Fig. 3H). In contrast, no changes were observed when
wild-type cells were analyzed.
These observations indicated that physiological concentrations
of 1,5AG lead to the accumulation of 1,5AG6P in G6PC3-
deficient neutrophils to concentrations that are sufficient to in-
hibit phosphorylation of glucose and reduce cell viability.
Phosphorylation of 1,5-Anhydroglucitol by Human Hexokinases and
ADPGK and Their Inhibition by 1,5-Anhydroglucitol-6-Phosphate.
Phosphorylation of 1,5AG likely results from a side activity of
a hexose-phosphorylating enzyme. To investigate this problem,
we produced human recombinant low-KM hexokinases (HK1,
HK2, and HK3) and ADP-glucokinase (ADPGK), and com-
pared their capacity to phosphorylate glucose and 1,5AG. The
kinetic constants (Table 1) show that low-KM hexokinases have a
low capacity to phosphorylate 1,5AG compared with glucose. In
vitro, catalytic efficiency values were indeed 104- to 105-fold
higher for glucose than they were for 1,5AG, consistent with
previous data obtained on brain hexokinase (HK1) (27). ADPGK,
on the other hand, phosphorylated 1,5AG with a catalytic effi-
ciency that was about 1/20 of that observed with glucose (Table 1).
Together, these findings suggest that in vivo, one cannot exclude
that the side activity of several enzymes may contribute to the
phosphorylation of 1,5AG.
To assess which enzymes could be affected by the accumulation
of 1,5AG6P, we measured the activity of recombinant hexokinases
in the presence of different concentrations of 1,5AG6P (Table 1).
While ADPGK was not inhibited even at the highest concentra-
tion of 1,5AG6P tested (1 mM), low-KM hexokinases showed in-
hibition constants well below the intracellular concentrations
measured in HAP1 cells (SI Appendix, Fig. S3 A and C) and in
mouse neutrophil progenitors (Fig. 3C). Thus, the concentrations
of 1,5AG6P that accumulated in these model systems are expec-
ted to inhibit glycolytic flux.
Modulating the Concentration of 1,5-Anhydroglucitol in Blood
Impacts Neutrophils in G6PC3-Deficient Mice. If 1,5AG6P is re-
sponsible for the toxicity observed in neutrophils, then 1,5AG
administration to G6PC3-deficient mice should exacerbate their
neutropenia. On the other hand, depletion of 1,5AG in the blood
by treatment with an inhibitor of the renal glucose transporter
SGLT2 (29, 30) should raise neutrophil numbers in these mice.
To test these predictions, we turned to a mouse model of G6PC3
deficiency.
When we administered empagliflozin to mice, the blood con-
centration of 1,5AG decreased by approximately fivefold in
5 d, while oral administration of 1,5AG increased the plasma
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Fig. 3. Toxicity of physiological concentrations of 1,5-anhydroglucitol in an immortalized mouse neutrophil precursor cell line deficient in G6PC3. (A) Cell
survival of estrogen-dependent immortalized mouse G6PC3-deficient neutrophil progenitors (ER-Hoxb8) was measured after 72-h culture in the presence of
the indicated concentrations of 1,5AG or 1,5-anhydrofructose (means ± SD; n = 3). (B) Glycolytic glucose utilization was indirectly evaluated by measuring the
detritiation of 2-[3H]glucose (at the phosphoglucose isomerase step) in the presence or absence of 0.2 mM 1,5AG (means ± SD; n = 3). (C–H) Intracellular
metabolites were analyzed by LC-MS/MS in extracts prepared from wild-type and G6PC3-deficient cells at different time points after addition of 0.2 mM
1,5AG (means ± SD; n = 6). Statistical analysis: (A) P values were determined with two-way ANOVA, and statistical significance was determined using the
Dunnett’s post hoc test for multiple comparisons (comparison of the treated with the untreated condition), with alpha = 0.05. (B–H) P values were determined with
multiple unpaired t tests (B: For each time point, one data point in one condition was compared with data points from the three other conditions; C–H: For each time
point, the G6PC3 KO was compared with the WT), and statistical significance was determined using the Holm–Sidak method, with alpha = 0.05. *P ≤ 0.05; ∋P ≤ 0.01;
∞P ≤ 0.001; $P ≤ 0.0001. DHAP, dihydroxyacetone-phosphate; F1,6P2, fructose-1,6-bisphosphate; G6P, glucose-6-phosphate; GA3P, glyceraldehyde-3-phosphate.
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concentration of this polyol by three- to fourfold; these changes
were independent of the mouse genotype (Fig. 4 A and B). Flow
cytometric analysis of Mac-1/Gr-1–positive leukocytes confirmed
that G6PC3-deficient mice were neutropenic and had on average
twofold fewer granulocytes than their heterozygous littermates
(Fig. 4C).
In a remarkable way, administration of empagliflozin achieved
an almost complete normalization of neutrophil numbers in G6PC3-
deficient mice. Since this change just failed to reach statistical sig-
nificance in the experiment shown in Fig. 4, we performed a second
experiment with an independent cohort of younger G6PC3-deficient
mice. Here, treatment with empagliflozin led to a highly significant
increase in neutrophil numbers, confirming that depletion of 1,5AG
can be used to treat neutropenia in these mice (SI Appendix, Fig. S4).
Conversely, when we orally administered 1,5AG to G6PC3-deficient
mice, Mac-1/Gr-1–positive granulocytes became barely detectable,
while this treatment had no impact in the heterozygous littermates
(Fig. 4C). LC-MS analysis of leukocytes revealed that those from
G6PC3-deficient mice accumulated about 200-fold more 1,5AG6P
compared with the heterozygous littermates. As expected, 1,5AG6P
levels were further increased by the administration of 1,5AG and
reduced by empagliflozin (Fig. 4D). Of note, glucose in blood from
G6PC3-deficient mice was neither significantly affected by empagli-
flozin nor by 1,5AG (107 ± 11 or 84 ± 9% compared with the un-
treated group, respectively). This indicates that variations in glucose
concentration did not play a role in the changes shown in Fig. 4.
Inspection of bone marrow smears indicated a maturation arrest
in G6PC3-deficient mice upon 1,5AG administration, with virtually
no mature neutrophils and abundant myeloperoxidase-positive
promyelocyte precursors (Fig. 4 F and H). The bone marrow of
heterozygous littermates treated in the same way showed a normal
granulocytopoietic hematopoiesis with plenty of mature neutrophils
(Fig. 4 E and G). We also tested the reversibility of the granulocyte
maturation arrest by treating G6PC3-deficient mice that were first
treated with 1,5AG with either empagliflozin, to rapidly lower the
levels of 1,5AG, or with saline as a control (SI Appendix, Fig. S5).
The rapid decrease in blood 1,5AG, as a result of empagliflozin
administration (SI Appendix, Fig. S4A), massively increased the
number of circulating granulocytes (SI Appendix, Fig. S5B and
Table S2) and reversed the maturation arrest in the bone marrow
(SI Appendix, Fig. S5 D and F). These effects were not observed
after the administration of saline (SI Appendix, Fig. S5 C and E).
These experiments demonstrated unequivocally that the mod-
ulation of 1,5AG concentrations with empagliflozin is of thera-
peutic value in G6PC3-deficient mice.
1,5-Anhydroglucitol-6-Phosphate Accumulates in Neutrophils from
Patients Deficient in G6PT or G6PC3. To assess whether compara-
ble pathogenic mechanisms are at play in neutrophils of human
patients, we analyzed blood samples from one patient with a
mutation in G6PC3 (PT3) and from two GSDIb patients with
mutations in G6PT (PT1 and PT2). All three patients were
neutropenic. PT2 was liver-transplanted ∼8 y ago and is currently
taking G-CSF. Further information concerning the patients’
pathology can be found in SI Appendix, Patient Information.
Polymorphonuclear cells (PMNs; mostly neutrophils) were sep-
arated from peripheral blood mononuclear cells (PBMCs; mostly
lymphocytes), and the concentration of 1,5AG6P was quantified.
Leukocytes from all three patients had a concentration of
1,5AG6P that was more than 500-fold higher than that measured
in controls (Fig. 5A), while the average concentration of 1,5AG in
plasma was not significantly different between patients and healthy
controls (Fig. 5B). Furthermore, the concentration of 1,5AG6P
was always higher in PMN cells compared with PBMCs in the same
patient (4.3- to 13-fold higher depending on the sample) (Fig. 5A).
Taken together, these results support the idea that G6PT and
G6PC3 are involved in the breakdown of 1,5AG6P in human
neutrophils and that, in their absence, 1,5AG6P reaches concen-
trations that are likely to inhibit hexokinases.
Discussion
The mechanism that we propose to explain the neutropenia/
neutrophil dysfunction seen in G6PT and G6PC3 deficiency is
illustrated in Fig. 6. 1,5AG, a polyol normally present in blood, is
slowly phosphorylated by a side activity of several glucose-
phosphorylating enzymes to 1,5AG6P. This compound is nor-
mally dephosphorylated by the combined action of G6PC3 and
G6PT. If not, it accumulates to concentrations that inhibit glu-
cose phosphorylation by low-KM hexokinases. Since mature neu-
trophils hardly have any functional mitochondria able to synthesize
ATP and mainly rely on glucose metabolism for energy production
(31, 32), it is likely that their maturation and function will be
greatly affected by the accumulation of 1,5AG6P.
Origin and Homeostasis of 1,5-Anhydroglucitol. 1,5AG, the major
polyol present in humans (33, 34) and rodents, essentially comes
from food, with little (<10%) endogenous production (35). It
results from the enzymatic reduction of 1,5-anhydrofructose,
which is produced by a minor side activity of glucosidases (36).
1,5AG is present in most foods at concentrations ranging from
0.3 to 3 μg·g−1 (35). The calculated daily intake in humans is
Table 1. Catalytic constants showing the specificity of human recombinant hexokinases 1, 2, and 3 and ADP-glucokinase for glucose
versus 1,5-anhydroglucitol and the inhibition constants for 1,5-anhydroglucitol-6-phosphate
Substrate: Glucose Substrate: 1,5AG Inhibitor: 1,5AG6P*
Enzyme KM, μM
Vmax,
μmol·min−1·mg−1
Kcat/KM,
s−1·μM−1 KM, mM
Vmax,
μmol·min−1·mg−1
Kcat/KM,
s−1·μM−1
Ratio Kcat/KM:
Glucose vs. 1,5AG Ki, μM
Δ21-hHK1†,‡ 50 ± 2 40 ± 0.5 1.36 57.9 ± 2.9 0.89 ± 0.03 2.6 × 10−5 52,308 53 ± 2
Δ28-hHK2†,‡ 250 ± 9 35.4 ± 0.4 0.25 126 ± 52 0.19 ± 0.06 0.26 × 10−5 96,153 96 ± 3
hHK3†,‡ 12.2 ± 1 10 ± 0.2 1.35 22.1 ± 3.9 1.2 ± 0.1 5.0 × 10−5 27,000 134 ± 9
Δ50-hADPG‡,§ 12.3 ± 1.3 5.2 ± 0.2 0.41 306 ± 36 7.0 ± 0.3 2.2 × 10−2 19 ¶
Data indicate means ± SEM (n ≥ 3).
*KI: noncompetitive inhibition versus glucose.
†Spectrophotometric assay: 0.5 mM ATP-Mg2+ and increasing concentrations of glucose or 1,5AG6P.
‡For optimal production, recombinant HK1, HK2, and ADPGK were expressed without hydrophobic N-terminal 21 (HK1), 28 (HK2), or 50 (ADPGK) amino acids
(see SI Appendix, Materials, Methods, and Patient Information for details).
§Radiochemical assay: 1 mM ADP-Mg2+ and increasing concentrations of glucose or 1,5AG6P.
¶No inhibition of hADPGK detected in the presence of 1 mM 1,5AG6P.
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about 4 mg, and the total body pool amounts to 500 to 1,000 mg.
There is extremely little metabolism of 1,5AG, and there is no
evidence that it has any physiological role (37). Its long half-life
(more than 3 mo) is due to its renal reabsorption at least in part by
SGLT4/SLC5A9 (38), a sodium-dependent sugar transporter
present in the kidney tubules, which is mainly a D-mannose
transporter but which also carries glucose, fructose, and 1,5AG.
Glucose competes with the kidney reuptake of 1,5AG, and this
explains that 1,5AG is eliminated in urine in diabetic patients who
have a blood glucose level above the renal threshold, or if they are
treated with gliflozins (39), which cause glucosuria by inhibiting
SGLT2, the main glucose transporter in the kidney (40).
Origin of 1,5-Anhydroglucitol-6-Phosphate and Its Impact on Glucose
Metabolism. Exploration of the kinetic properties of G6PC3 led
us to find that this enzyme dephosphorylates several phosphate
esters better than glucose-6-P. Studies on intact microsomes in-
volving the G6PT inhibitor S3483 indicated that one of these
phosphate esters, 1,5AG6P, requires the glucose-6-P transporter
G6PT/SLC37A4 to be hydrolyzed by G6PC3. Not unexpectedly,
1,5AG6P is structurally closer to glucose-6-P than are other
phosphate esters that were apparently not transported by G6PT.
Involvement of both G6PC3 and G6PT in the hydrolysis of
1,5AG6P was further supported by the fact that 1,5AG6P ac-
cumulates in G6PC3- or G6PT-deficient cells incubated with
1,5AG or 1,5-anhydrofructose, a compound that is readily con-
verted in the cells to 1,5AG.
Accumulation of 1,5AG6P under these conditions indicates
the presence of enzymes capable of phosphorylating the polyol
on its sixth carbon. Our studies with recombinant enzymes in-
dicate that several enzymes that normally phosphorylate glucose
can also phosphorylate 1,5AG. In vitro, these include low-KM
hexokinases and mainly ADPGK, which is an ADP-dependent
glucose kinase with an enigmatic function and which was until
A
E
G
B
C
D
F
H
Fig. 4. Modulating the concentration of 1,5-anhydroglucitol in blood impacts neutrophils in G6PC3-deficient mice. G6PC3 KO or heterozygous littermates
(8 to 11 wk old; 20 to 24 g) were left untreated or treated with 100 μL of an empagliflozin (EMPA) suspension (10 mg·kg−1; 10 times over 14 d) or 1,5AG
(100 μL of a 50 mM solution; five times from day 7) until euthanasia on day 14 (n = 6 to 8 for each group). (A and B) 1,5AG in serum was measured at the
indicated time points by LC-MS analysis (A) or from plasma recovered from EDTA-blood collected after euthanasia (B). (C) Flow cytometry analysis with anti–
Mac-1 (CD11b-PE) and anti–Gr-1 (Ly-6G-FITC) antibodies was performed to quantify granulocytes. (D) LC-MS analysis of 1,5AG6P in extracts from isolated
white blood cells (WBCs). (E–H) Bone marrow smears from 1,5AG-treated G6PC3 heterozygous (E and G) or knockout (F and H) mice were stained with May–
Grünwald (E and F) or peroxidase (G and H), showing a maturation arrest with accumulation of apparent promyelocytes (“P”) in G6PC3 KO mice (F and H) and
normal maturation with plenty of mature neutrophils (“N”) in heterozygous mice (E and G), and confirming the myeloid nature of these cells (peroxidase-
positive in G and H). (Scale bar, 20 μm.) Statistical analysis: (A–D) P values were determined with one-way ANOVA followed by multiple t tests using the
Bonferroni correction, with alpha = 0.05. Data are means ± SD (n = 6 to 8). ns, not significant, P > 0.05; ∋P ≤ 0.01; ∞P ≤ 0.001; $P ≤ 0.0001. (Magnification: G, 100×.)
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now considered to be very specific for glucose (41). Intriguingly,
this enzyme is associated with the endoplasmic reticulum, but
appears to have its catalytic site oriented toward the cytosol (42).
Hexokinase 1, hexokinase 3, and ADPGK are present in neu-
trophils. In vitro, the human low-KM hexokinases phosphorylated
1,5AG with a much lower catalytic efficiency than ADPGK
(Table 1), which suggested that the latter might be the main
enzyme involved in 1,5AG phosphorylation. However, the rela-
tive contribution of these kinases to 1,5AG6P formation in cells
also depends on their relative abundance, which is not known,
and on the presence of competing substrates (mainly glucose)
and inhibitors (glucose-6-P). It is therefore not possible at pre-
sent to know which kinase contributes the most to the production
of 1,5AG6P in vivo.
Low-KM hexokinases are physiologically inhibited by their
product glucose-6-P. Previous studies performed with glucose-6-
P analogs on brain hexokinase (hexokinase 1) (27) showed that
1,5AG6P is also a good inhibitor, while mannose-6-P and 2-
deoxyglucose-6-P are not. This points to the importance of a
hydroxyl group in the appropriate orientation on carbon 2, as
present in glucose-6-P and 1,5AG6P, for the inhibitory effect to
take place. Here, we showed with human recombinant enzymes
that the inhibition by 1,5AG6P is also found with hexokinases
2 and 3. As hexokinase 3 is the main glucose-phosphorylating
enzyme in neutrophils (43) and in agreement with its Ki for
1,5AG6P (150 μM), the accumulation of 1,5AG6P that is seen in
G6PC3 or G6PT deficiencies is expected to inhibit glucose
phosphorylation. From the data obtained with neutrophils, we
estimate that the intracellular concentration reaches ∼3 mM in a
mouse ER-Hox8b G6PC3-deficient neutrophil progenitor cell
line grown in the presence of physiological concentrations of
1,5AG (Fig. 3C) as well as in human neutrophils isolated from
blood samples of G6PC3-deficient or GSDIb patients (Fig. 5A).
Taking into account that this inhibition is competitive with re-
spect to ATP (44), we calculate that this concentration is suffi-
cient to cause more than 80% inhibition of hexokinase activity at
a physiological concentration of 2.5 mM ATP. This is consistent
with data obtained on leukocytes from GSDIb patients, which
indicated that the defect found in these cells is due to a reduction
in glucose phosphorylation, while glucose entry, as assessed with the
nonphosphorylatable glucose analog 3-O-methyl glucose, is unaf-
fected (45). These observations might seem at odds with the pre-
vious claim that G6PC3-deficient neutrophils show a decreased
uptake of glucose (11). However, in the latter study, 2-deoxyglucose
was used to assess glucose uptake, despite the fact that it measures
a combination of hexose entry and phosphorylation (46). Further-
more, another confounding factor in this study might have been
that the G6PC3-deficient neutrophils have decreased viability and
that this on its own could reduce glucose phosphorylation and
glucose uptake. Thus, all published data are consistent with an in-
hibition of glucose phosphorylation rather than of glucose entry.
Accumulation of 1,5-Anhydroglucitol-6-Phosphate Leads to Neutropenia.
Neutrophils are extremely sensitive to a reduction of glucose
metabolism. This is believed to be due to the fact that they have a
limited number of mitochondria, which furthermore hardly dis-
play any marker of mitochondrial enzymatic activity and do not
synthesize much ATP (31, 32). They therefore mainly rely on
glycolysis for their metabolism and energy supply (31). A re-
duction in glucose phosphorylation, due to a defect in the de-
phosphorylation of 1,5AG6P, may therefore explain several of
the deficiencies that have been observed in G6PC3- or G6PT-
deficient neutrophils. Indeed, decreased neutrophil motility and
defects in respiratory burst (likely due to a reduction in NADPH
production) that lead to an increased susceptibility to bacterial
infection (1, 2) can be explained by the inhibition of glucose
phosphorylation due to the accumulation of 1,5AG6P in pa-
tients’ neutrophils. Furthermore, reduced levels of glucose-6-P
are expected to compromise synthesis of NDP-sugars, leading to
the observed defects in protein glycosylation in G6PC3- and
G6PT-deficient neutrophils (10). Of note, accumulation of
1,5AG6P might also explain the functional defects in macro-
phages in G6PC3-deficient mice, as these cells also show a re-
duction in glucose uptake and lower levels of glucose-6-P,
lactate, and ATP compared with wild-type mice (47).
Patients with G6PT or G6PC3 deficiency show an arrest in
neutrophil maturation at the myelocytic and promyelocytic stage
(48). When we treated G6PC3-deficient mice with 1,5AG, we
observed evidence for an arrest at this stage in the bone marrow.
In contrast, treatment with the SGLT2 inhibitor empagliflozin
released the blockage and allowed neutrophil maturation (SI
Appendix, Fig. S5). This suggests that accumulation of 1,5AG6P
is responsible for the maturation arrest.
The best proof that the effect of 1,5AG6P is the main, if not
the sole, explanation for the neutrophil defect in G6PC3 and
G6PT deficiencies is the finding that neutrophil toxicity is eli-
cited by the addition of 1,5AG to cultures of neutrophil pre-
cursors and that the administration of 1,5AG to mice further
decreases their neutrophil counts, while reducing the concen-
tration of 1,5AG considerably increases their number.
Lowering of Blood 1,5-Anhydroglucitol Can Treat Neutropenia. Our
observation that modulating the concentration of blood 1,5AG
in G6PC3-deficient mice strongly impacted neutrophil counts
opens perspectives for the treatment of the neutropenias caused
by G6PT or G6PC3 deficiencies. 1,5AG is widely distributed in
food and has a long half-life (more than 3 mo) (49); therefore,
limiting the food intake of this polyol is difficult to achieve and in
A
B
Fig. 5. 1,5-Anhydroglucitol-6-phosphate accumulates in neutrophils from
patients deficient in G6PT or G6PC3. (A) Concentration of 1,5AG6P was de-
termined by LC-MS in granulocytes (PMNs) and lymphocytes (PBMCs)
obtained from patients and healthy controls. (B) Serum 1,5AG in two GSDIb
(filled symbols) and one G6PC3-deficient (open symbols) patients and seven
healthy controls (CT) was determined by LC-MS (each symbol represents a
different control; for some individuals, blood samples were taken on two
different occasions to estimate variability and the two values are shown).
PT2: GSDIb is treated with G-CSF.
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any case would be effective only after several weeks. Therapies
aimed at enhancing the urinary excretion of 1,5AG should there-
fore be much more effective. Indeed, administration of the
SGLT2 inhibitor empagliflozin to mice led in a few days to a >80%
decrease in the plasma concentration of 1,5AG. Of note, given the
slow turnover of the 1,5AG pool, it is likely that an intermittent
therapy with this drug might suffice to treat neutropenia.
The potential drawback of such treatment is that it causes
glucosuria, which may therefore lead to hypoglycemia, particularly
in G6PT-deficient patients, because of their reduced capacity of
producing glucose (unless they have been liver-transplanted). This
drawback has to be kept in balance with the side effects of the G-
CSF therapy, which is used in the most severely affected patients.
G-CSF administration may indeed be painful and result in an
increased risk of development of myelodysplastic syndrome or
acute myeloid leukemia (50).
Can Other Symptoms in Patients with G6PC3 Deficiency Also Be
Explained by the Accumulation of 1,5AG6P? Patients with G6PC3
deficiency do not only present with neutropenia but also with
cardiac, urogenital, and venous malformations (2), which are not
observed in patients with G6PT deficiency. These symptoms might
be caused by the accumulation of 1,5AG6P in the endoplasmic
reticulum of specific cell types, which is not expected to occur in
G6PT deficiency. Alternatively, it is possible that the accumulation
of a G6PC3 substrate, other than 1,5AG6P, is responsible for these
changes. The role of this accumulation and the identification of
additional G6PC3 substrates deserves further studies.
Concluding Remarks
In conclusion, G6PC3, in collaboration with G6PT, catalyzes a
new metabolite-repair reaction, and their deficiencies qualify
therefore as diseases of metabolite repair. This new example
adds to the growing list of metabolite-repair reactions, which
is probably still far from complete. In the present case, the
identification of the nonclassical metabolite that exerts toxic
effects (1,5AG6P) leads to therapeutic perspectives. This
should further motivate the search for other metabolite-
repair reactions and their involvement in unclear metabolic
diseases.
Materials and Methods
Detailed procedures involving the creation of knockout cell lines and cell
culturing, production, and purification of recombinant proteins, enzymatic
assays, LC-MS and GC-MS metabolite analysis, establishment of G6PC3-
deficient mouse models and experiments involving the effect of modulat-
ing the blood concentration of 1,5AG on neutropenia in these mice, and
isolation of leukocytes from human G6PC3- and G6PT-deficient patients and
their metabolite analysis are described in SI Appendix, Materials, Methods,
and Patient Information. All procedures involving mice were performed
following protocols accepted by the UCLouvain Animal Care Ethics Com-
mittee. Every effort was made to minimize mouse suffering. The blood
samples in the experiments involving human blood were deidentified before
use in experiments, informed consent was obtained, and followed protocols
accepted by the Human Ethics Committee from Cliniques Universitaires
Saint-Luc, UCLouvain.
ACKNOWLEDGMENTS. We thank Susanne Kirschnek and Georg Häcker (In-
stitute for Medical Microbiology and Hygiene, University Medical Center,
Freiburg) for kindly providing the estrogen-dependent immortalized
mouse wild-type and G6PC3-deficient neutrophil progenitors (ER-Hoxb8)
and advising on culture conditions; Feng Zhang (Massachusetts Institute
of Technology) for providing the plasmids used to clone the guide RNAs
in the CRISPR-Cas9 experiments; and Maude Minsart and Nathalie Greisch
for helping with G6PC3 and hexokinase experiments. Funding was pro-
vided by WELBIO (CR-2015A-09), FNRS (Fonds National de la Recherche
Scientifique) (J.0104.18 to M.V.-d.-C.; J.0139.18 to E.V.S.; and F-4509.17 to
G.T.B.), Fondation Contre le Cancer (2016-075 to G.T.B.), and Fonds Joseph
Fig. 6. Illustration of the role played by 1,5-anhydroglucitol-6-phosphate accumulation in the neutropenia found in G6PC3 and G6PT deficiency. 1,5AG (also
called 1-deoxyglucose) is a polyol that resembles glucose and is normally present in blood. It is transported into neutrophils and slowly phosphorylated by a
side activity of low-KM hexokinases (HK1, HK2, and HK3) and ADP-dependent glucokinase to 1,5AG6P. The glucose-6-P transporter of the endoplasmic re-
ticulum (G6PT) transports 1,5AG6P into the ER, where it is dephosphorylated by G6PC3. When patients are deficient in G6PT or G6PC3, 1,5AG6P accumulates
in neutrophils to concentrations that strongly inhibit low-KM hexokinases, the enzymes catalyzing the first step of glycolysis. This depletes the intracellular
pool of glucose-6-P in granulocytes, which likely decreases ATP production in glycolysis, as well as likely NADPH production in the pentose-P pathway and also
UDP-glucose availability for protein glycosylation, explaining neutrophil dysfunction and neutropenia described in these patients.
Veiga-da-Cunha et al. PNAS Latest Articles | 9 of 10
BI
O
CH
EM
IS
TR
Y
Maisin, European Research Council (NOMEPACA 771704 to G.T.B.). M.V.-d.-C.
and G.T.B. are “Chercheur qualifié,” and J.P.D. is an “Aspirant” of the FNRS.
We thank the Association Luxembourgeoise des Amis de la Fondation
Louvain for their donation to this research. N.P. was supported by a CORE
junior grant (C16/BM/11339953) of the Fonds National de la Recherche
Luxembourg.
1. Boztug K, et al. (2009) A syndrome with congenital neutropenia and mutations in
G6PC3. N Engl J Med 360:32–43.
2. Cheung YY, et al. (2007) Impaired neutrophil activity and increased susceptibility to
bacterial infection in mice lacking glucose-6-phosphatase-beta. J Clin Invest 117:
784–793.
3. Veiga-da-Cunha M, et al. (1998) A gene on chromosome 11q23 coding for a putative
glucose-6-phosphate translocase is mutated in glycogen-storage disease types Ib and
Ic. Am J Hum Genet 63:976–983.
4. Martin CC, et al. (2002) Identification and characterization of a human cDNA and
gene encoding a ubiquitously expressed glucose-6-phosphatase catalytic subunit-
related protein. J Mol Endocrinol 29:205–222.
5. Boustead JN, et al. (2004) Identification and characterization of a cDNA and the gene
encoding the mouse ubiquitously expressed glucose-6-phosphatase catalytic subunit-
related protein. J Mol Endocrinol 32:33–53.
6. Shieh JJ, Pan CJ, Mansfield BC, Chou JY (2003) A glucose-6-phosphate hydrolase,
widely expressed outside the liver, can explain age-dependent resolution of hypo-
glycemia in glycogen storage disease type Ia. J Biol Chem 278:47098–47103.
7. Shieh JJ, Pan CJ, Mansfield BC, Chou JY (2004) A potential new role for muscle in
blood glucose homeostasis. J Biol Chem 279:26215–26219.
8. Bali DS, Chen YT, Austin S, Goldstein JL (2006) Glycogen storage disease type I.
Available at https://www.ncbi.nlm.nih.gov/books/NBK1312/. Accessed September 10,
2018.
9. Gerin I, Veiga-da-CunhaM, Achouri Y, Collet JF, Van Schaftingen E (1997) Sequence of
a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type
Ib. FEBS Lett 419:235–238.
10. Hayee B, et al. (2011) G6PC3 mutations are associated with a major defect of glyco-
sylation: A novel mechanism for neutrophil dysfunction. Glycobiology 21:914–924.
11. Jun HS, et al. (2010) Lack of glucose recycling between endoplasmic reticulum and
cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient
neutrophils in a congenital neutropenia syndrome. Blood 116:2783–2792.
12. Marcolongo P, et al. (2013) Multiple roles of glucose-6-phosphatases in pathophysi-
ology: State of the art and future trends. Biochim Biophys Acta 1830:2608–2618.
13. Linster CL, Van Schaftingen E, Hanson AD (2013) Metabolite damage and its repair or
pre-emption. Nat Chem Biol 9:72–80.
14. Van Schaftingen E, et al. (2013) Metabolite proofreading, a neglected aspect of in-
termediary metabolism. J Inherit Metab Dis 36:427–434.
15. Linster CL, et al. (2011) Ethylmalonyl-CoA decarboxylase, a new enzyme involved in
metabolite proofreading. J Biol Chem 286:42992–43003.
16. Adler LN, Gomez TA, Clarke SG, Linster CL (2011) A novel GDP-D-glucose phosphor-
ylase involved in quality control of the nucleoside diphosphate sugar pool in Cae-
norhabditis elegans and mammals. J Biol Chem 286:21511–21523.
17. Collard F, et al. (2016) A conserved phosphatase destroys toxic glycolytic side products
in mammals and yeast. Nat Chem Biol 12:601–607.
18. Peracchi A, et al. (2017) Nit1 is a metabolite repair enzyme that hydrolyzes de-
aminated glutathione. Proc Natl Acad Sci USA 114:E3233–E3242.
19. Veiga-da-Cunha M, Chevalier N, Stroobant V, Vertommen D, Van Schaftingen E
(2014) Metabolite proofreading in carnosine and homocarnosine synthesis: Molecular
identification of PM20D2 as β-alanyl-lysine dipeptidase. J Biol Chem 289:19726–19736.
20. Rzem R, et al. (2015) A mouse model of L-2-hydroxyglutaric aciduria, a disorder of
metabolite repair. PLoS One 10:e0119540.
21. Rzem R, Vincent MF, Van Schaftingen E, Veiga-da-Cunha M (2007) L-2-hydroxyglutaric
aciduria, a defect of metabolite repair. J Inherit Metab Dis 30:681–689.
22. Kremer LS, et al. (2016) NAXE mutations disrupt the cellular NAD(P)HX repair system
and cause a lethal neurometabolic disorder of early childhood. Am J Hum Genet 99:
894–902.
23. Van Schaftingen E, Gerin I (2002) The glucose-6-phosphatase system. Biochem J 362:
513–532.
24. Hemrika W, Wever R (1997) A new model for the membrane topology of glucose-6-
phosphatase: The enzyme involved in von Gierke disease. FEBS Lett 409:317–319.
25. Arion WJ, et al. (1998) Chlorogenic acid analogue S 3483: A potent competitive in-
hibitor of the hepatic and renal glucose-6-phosphatase systems. Arch Biochem
Biophys 351:279–285.
26. Sakuma M, Kametani S, Akanuma H (1998) Purification and some properties of a
hepatic NADPH-dependent reductase that specifically acts on 1,5-anhydro-D-fructose.
J Biochem 123:189–193.
27. Crane RK, Sols A (1954) The non-competitive inhibition of brain hexokinase by
glucose-6-phosphate and related compounds. J Biol Chem 210:597–606.
28. Gautam S, et al. (2013) Survival and differentiation defects contribute to neutropenia
in glucose-6-phosphatase-β (G6PC3) deficiency in a model of mouse neutrophil
granulocyte differentiation. Cell Death Differ 20:1068–1079.
29. Hohendorff J, et al. (2017) A single dose of dapagliflozin, an SGLT-2 inhibitor, induces
higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Endocrine 57:272–279.
30. Fortuna D, McCloskey LJ, Stickle DF (2016) Model analysis of effect of canagliflozin
(Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhy-
droglucitol. Clin Chim Acta 452:138–141.
31. Borregaard N, Herlin T (1982) Energy metabolism of human neutrophils during
phagocytosis. J Clin Invest 70:550–557.
32. Maianski NA, et al. (2004) Functional characterization of mitochondria in neutrophils:
A role restricted to apoptosis. Cell Death Differ 11:143–153.
33. Pitkänen E (1982) Serum 1,5-anhydroglucitol in normal subjects and in patients with
insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 42:445–448.
34. Pitkänen E (1990) 1,5-Anhydro-D-glucitol—A novel type of sugar in the human or-
ganism. Scand J Clin Lab Invest Suppl 201:55–62.
35. Yamanouchi T, et al. (1992) Origin and disposal of 1,5-anhydroglucitol, a major polyol
in the human body. Am J Physiol 263:E268–E273.
36. Yu S (2008) The anhydrofructose pathway of glycogen catabolism. IUBMB Life 60:
798–809.
37. Mizuno H, Morita M, Akanuma H (1995) Phosphorylation of 1,5-anhydro-D-glucitol in
mammalian cells. J Biochem 118:411–417.
38. Tazawa S, et al. (2005) SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is
an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 76:
1039–1050.
39. Balis DA, Tong C, Meininger G (2014) Effect of canagliflozin, a sodium-glucose co-
transporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol. J Diabetes 6:
378–380.
40. Chao EC, Henry RR (2010) SGLT2 inhibition—A novel strategy for diabetes treatment.
Nat Rev Drug Discov 9:551–559.
41. Richter JP, Goroncy AK, Ronimus RS, Sutherland-Smith AJ (2016) The structural and
functional characterization of mammalian ADP-dependent glucokinase. J Biol Chem
291:3694–3704.
42. Kaminski MM, et al. (2012) T cell activation is driven by an ADP-dependent glucoki-
nase linking enhanced glycolysis with mitochondrial reactive oxygen species gener-
ation. Cell Rep 2:1300–1315.
43. Rijksen G, Staal GE, Beks PJ, Streefkerk M, Akkerman JW (1982) Compartmentation of
hexokinase in human blood cells. Characterization of soluble and particulate en-
zymes. Biochim Biophys Acta 719:431–437.
44. Wilson JE, Chung V (1989) Rat brain hexokinase: Further studies on the specificity of
the hexose and hexose 6-phosphate binding sites. Arch Biochem Biophys 269:
517–525.
45. Potashnik R, Moran A, Moses SW, Peleg N, Bashan N (1990) Hexose uptake and
transport in polymorphonuclear leukocytes from patients with glycogen storage
disease Ib. Pediatr Res 28:19–23.
46. Bashan N, et al. (1993) Deficient glucose phosphorylation as a possible common de-
nominator and its relation to abnormal leucocyte function, in glycogen storage dis-
ease 1b patients. Eur J Pediatr 152:S44–S48.
47. Jun HS, Cheung YY, Lee YM, Mansfield BC, Chou JY (2012) Glucose-6-phosphatase-β,
implicated in a congenital neutropenia syndrome, is essential for macrophage energy
homeostasis and functionality. Blood 119:4047–4055.
48. Gitzelmann R, Bosshard NU (1993) Defective neutrophil and monocyte functions in
glycogen storage disease type Ib: A literature review. Eur J Pediatr 152:S33–S38.
49. Yamanouchi T, et al. (1995) Prolonged hyperalimentation as a possible cause of renal tubular
dysfunction: Evaluation of 1,5-anhydro-D-glucitol resorption and N-acetylglucosaminidase
excretion in humans. Clin Sci (Lond) 88:203–210.
50. Li AM, et al. (2018) Prolonged granulocyte colony stimulating factor use in glycogen
storage disease type 1b associated with acute myeloid leukemia and with shortened
telomere length. Pediatr Hematol Oncol 35:45–51.
51. Benjamini Y, Krieger AM, Yekutieli D (2006) Adaptive linear step-up procedures that
control the false discovery rate. Biometrika 93:491–507.
10 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.1816143116 Veiga-da-Cunha et al.
